Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Consensus Rating of “Moderate Buy” from Analysts

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has received an average rating of “Moderate Buy” from the seven analysts that are currently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $16.60.

A number of brokerages have weighed in on AMRX. UBS Group lifted their price objective on Amneal Pharmaceuticals from $19.00 to $23.00 and gave the company a “buy” rating in a report on Wednesday. Wall Street Zen raised Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, July 12th. Zacks Research downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Weiss Ratings lowered Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, May 26th. Finally, Barclays increased their price objective on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 20th.

Insider Activity at Amneal Pharmaceuticals

In related news, Director Deborah M. Autor sold 34,819 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $12.94, for a total value of $450,557.86. Following the completion of the sale, the director owned 93,660 shares in the company, valued at $1,211,960.40. This trade represents a 27.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 17.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Kemnay Advisory Services Inc. acquired a new stake in shares of Amneal Pharmaceuticals in the 4th quarter worth approximately $26,000. Federated Hermes Inc. raised its holdings in Amneal Pharmaceuticals by 1,680.6% during the fourth quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after purchasing an additional 2,168 shares during the last quarter. Comerica Bank boosted its position in Amneal Pharmaceuticals by 186.7% during the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after purchasing an additional 1,957 shares in the last quarter. Spire Wealth Management boosted its position in Amneal Pharmaceuticals by 66.6% during the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after purchasing an additional 1,023 shares in the last quarter. Finally, Transamerica Financial Advisors LLC grew its holdings in Amneal Pharmaceuticals by 541.9% in the fourth quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock valued at $37,000 after purchasing an additional 2,460 shares during the last quarter. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Stock Performance

NASDAQ:AMRX opened at $17.85 on Monday. Amneal Pharmaceuticals has a 12-month low of $7.66 and a 12-month high of $18.39. The stock’s 50 day simple moving average is $15.05 and its 200-day simple moving average is $13.90. The firm has a market cap of $5.69 billion, a P/E ratio of 46.97 and a beta of 1.26.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. The firm had revenue of $722.52 million for the quarter. Research analysts forecast that Amneal Pharmaceuticals will post 0.92 EPS for the current fiscal year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.